{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:28Z","timestamp":1787020168070,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province","award":["CXPJJH121003-2115"],"award-info":[{"award-number":["CXPJJH121003-2115"]}]},{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","award":["WJ2107M185"],"award-info":[{"award-number":["WJ2107M185"]}],"id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the effect of sacubitril valsartan (SV) on heart failure (HF) hospitalization and cardiovascular mortality in patients on hemodialysis with HF with preserved ejection fraction (EF; HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center, prospective study enrolled 155 stable hemodialysis patients with EF\u2009&gt;\u200940% who were followed up for 12 months. Fifty-nine patients were treated with SV; the others were matched for EF (57.89\u2009\u00b1\u20099.35 vs. 58.00\u2009\u00b1\u200911.82,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.9) at a ratio of 1:1 and included as controls. The target dosage of SV was 200\u00a0mg\/day.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-three (23\/155; 14.84%) had HF with mid-range EF (HFmrEF), while 132 (85.16%) had HFpEF. After SV treatment, the peak early diastolic transmitral flow velocity\/peak early diastolic mitral annular tissue velocity(E\/e\u2019) improved from 17.19\u2009\u00b1\u20098.74 to 12.80\u2009\u00b1\u20095.52 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006), the left ventricular (LV) end-diastolic diameter decreased from 53.14\u2009\u00b1\u20097.67\u00a0mm to 51.56\u2009\u00b1\u20097.44\u00a0mm (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03), and the LV mass index decreased from 165.7\u2009\u00b1\u200944.6\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      to 154.8\u2009\u00b1\u200924.0\u00a0g\/m\n                      <jats:sup>2<\/jats:sup>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). LVEF (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.08) and LV global longitudinal strain (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7) did not change significantly. The composite outcome of first and recurrent HF hospitalization or cardiovascular death showed no difference between group. However, the Acute Dialysis Quality Initiative Workgroup (ADQI) HF class improved in 39 and 15 patients and worsened in 1 and 11 patients in the SV and control groups, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Age, diabetes mellitus, and pulmonary arterial pressure were independent risk factors for HF hospitalization and cardiovascular mortality in patients with HFpEF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SV improved LV hypertrophy, diastolic function, and the ADQI class for HF; however, it failed to reduce the composite endpoints of HF hospitalization and cardiovascular disease-related mortality over 12 months of follow-up in patients on maintenance hemodialysis with EF of &gt;\u200940%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-024-03744-y","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T07:02:47Z","timestamp":1706598167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiao-mei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-ling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"3744_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"key":"3744_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","volume":"15","author":"C de Diego","year":"2018","unstructured":"de Diego C, Gonz\u00e1lez-Torres L, N\u00fa\u00f1ez JM, Centuri\u00f3n Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15:395\u2013402. https:\/\/doi.org\/10.1016\/j.hrthm.2017.11.012.","journal-title":"Heart Rhythm"},{"key":"3744_CR3","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/s0735-1097(03)00185-2","volume":"41","author":"GL Smith","year":"2003","unstructured":"Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510\u20138. https:\/\/doi.org\/10.1016\/s0735-1097(03)00185-2.","journal-title":"J Am Coll Cardiol"},{"key":"3744_CR4","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.074.","journal-title":"J Am Coll Cardiol"},{"key":"3744_CR5","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1002\/ehf2.13760","volume":"8","author":"L Stretti","year":"2021","unstructured":"Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, Coats, et al. A year in heart failure: an update of recent findings. ESC Heart Fail. 2021;8:4370\u201393. https:\/\/doi.org\/10.1002\/ehf2.13760.","journal-title":"ESC Heart Fail"},{"key":"3744_CR6","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"key":"3744_CR7","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142:1236\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047643.","journal-title":"Circulation"},{"key":"3744_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6:489\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004.","journal-title":"JACC Heart Fail"},{"key":"3744_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ehf2.12659","volume":"7","author":"S Lee","year":"2020","unstructured":"Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, et al. Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020;7:1125\u20139. https:\/\/doi.org\/10.1002\/ehf2.12659.","journal-title":"ESC Heart Fail"},{"key":"3744_CR10","doi-asserted-by":"publisher","unstructured":"Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;28\u201334. https:\/\/doi.org\/10.1093\/ndt\/gfy174. 33;Suppl 3:iii.","DOI":"10.1093\/ndt\/gfy174"},{"key":"3744_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2369-13-94","volume":"13","author":"F Hou","year":"2012","unstructured":"Hou F, Jiang J, Chen J, Yu X, Zhou Q, Chen P, et al. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. BMC Nephrol. 2012;13:94. https:\/\/doi.org\/10.1186\/1471-2369-13-94.","journal-title":"BMC Nephrol"},{"key":"3744_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17:559\u201373. https:\/\/doi.org\/10.1038\/s41569-020-0363-2.","journal-title":"Nat Rev Cardiol"},{"key":"3744_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","volume":"73","author":"K McHugh","year":"2019","unstructured":"McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602\u201311. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.033.","journal-title":"J Am Coll Cardiol"},{"key":"3744_CR14","doi-asserted-by":"publisher","unstructured":"Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA et al. Proposal for a functional classification system of heart failure in patients with end-stage renal disease: Proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. Proceedings of the acute dialysis quality initiative (ADQI) XI. J Am Coll Cardiol. 2014;63:1246-52. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.020.","DOI":"10.1016\/j.jacc.2014.01.020"},{"key":"3744_CR15","doi-asserted-by":"publisher","unstructured":"Echocardiography group of ultrasound medicine branch of Chinese Medical Association, echocardiography committee of cardiovascular branch of Chinese Physicians Association. Clinical guidelines for echocardiographic assessment of cardiac systolic and diastolic function. Chin J Ultrasound Imaging. 2020;29:461\u2009\u2013\u200978. https:\/\/doi.org\/10.3760\/cmajcn131148-20200227-00115.","DOI":"10.3760\/cmajcn131148-20200227-00115"},{"key":"3744_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1\u201364. https:\/\/doi.org\/10.1016\/j.echo.2018.06.004.","journal-title":"J Am Soc Echocardiogr"},{"key":"3744_CR17","doi-asserted-by":"publisher","unstructured":"Hemodialysis Adequacy Collaborative Group. Nephrologists branch, Chinese physicians association. Clinical practice guidelines for adequacy of hemodialysis in China. Chin Med J (Engl) (China). 2015;95:2748-53. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2015.34.004.","DOI":"10.3760\/cma.j.issn.0376-2491.2015.34.004"},{"issue":"4","key":"3744_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/clinchem\/hvab282","volume":"68","author":"JW Meeusen","year":"2022","unstructured":"Meeusen JW, Kasozi RN, Larson TS, Lieske JC. Clinical impact of the Refit CKD-EPI 2021 Creatinine-based eGFR equation. Clin Chem. 2022;68(4):534\u20139. https:\/\/doi.org\/10.1093\/clinchem\/hvab282.","journal-title":"Clin Chem"},{"key":"3744_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/ki.2015.117","volume":"88","author":"KU Eckardt","year":"2015","unstructured":"Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P, Anker SD, et al. High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int. 2015;88:1117\u201325. https:\/\/doi.org\/10.1038\/ki.2015.117.","journal-title":"Kidney Int"},{"key":"3744_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2215\/CJN.00490119","volume":"14","author":"M Allon","year":"2019","unstructured":"Allon M. Vascular access for hemodialysis patients: New data should guide decision making. Clin J Am Soc Nephrol. 2019;14:954\u201361. https:\/\/doi.org\/10.2215\/CJN.00490119.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3744_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3760\/cma.j.cn441217-20210812-00068","volume":"38","author":"Chinese Society of Nephrology","year":"2022","unstructured":"Chinese Society of Nephrology. Zhongguancun nephrology and blood purification innovation alliance, guidelines for the management of chronic heart failure in dialysis patients in China. Chin J Nephrol. 2022;38:465\u201396. https:\/\/doi.org\/10.3760\/cma.j.cn441217-20210812-00068.","journal-title":"Chin J Nephrol"},{"key":"3744_CR22","doi-asserted-by":"publisher","first-page":"877237","DOI":"10.3389\/fmed.2022.877237","volume":"9","author":"L Gan","year":"2022","unstructured":"Gan L, Lyu X, Yang X, Zhao Z, Tang Y, Chen Y, et al. Application of angiotensin receptor-neprilysin inhibitor in chronic kidney disease patients: Chinese expert consensus. Front Med (Lausanne). 2022;9:877237. https:\/\/doi.org\/10.3389\/fmed.2022.877237.","journal-title":"Front Med (Lausanne)"},{"key":"3744_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/jch.14422","volume":"24","author":"B Wang","year":"2022","unstructured":"Wang B, Wang GH, Ding XX, Tang HX, Zheng J, Liu BC, et al. Effects of Sacubitril\/Valsartan on resistant hypertension and myocardial work in hemodialysis patients. J Clin Hypertens (Greenwich). 2022;24:300\u20138. https:\/\/doi.org\/10.1111\/jch.14422.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3744_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000519643","volume":"51","author":"Z Feng","year":"2022","unstructured":"Feng Z, Wang X, Zhang L, Apaer R, Xu L, Ma J, et al. Pharmacokinetics and pharmacodynamics of Sacubitril\/Valsartan in maintenance hemodialysis patients with heart failure. Blood Purif. 2022;51:270\u20139. https:\/\/doi.org\/10.1159\/000519643.","journal-title":"Blood Purif"},{"key":"3744_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","volume":"7","author":"AM Shah","year":"2014","unstructured":"Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O\u2019Meara E, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circ Heart Fail. 2014;7:740\u201351. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001583.","journal-title":"Circ Heart Fail"},{"key":"3744_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","volume":"132","author":"AM Shah","year":"2015","unstructured":"Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation. 2015;132:402\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.015884.","journal-title":"Circulation"},{"key":"3744_CR27","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","volume":"74","author":"AM Shah","year":"2019","unstructured":"Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74:2858\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.063.","journal-title":"J Am Coll Cardiol"},{"key":"3744_CR28","doi-asserted-by":"publisher","first-page":"e016009","DOI":"10.1161\/JAHA.119.016009","volume":"9","author":"FF Wei","year":"2020","unstructured":"Wei FF, Xue R, Thijs L, Liang W, Owusu-Agyeman M, He X, et al. Associations of left ventricular structure and function with blood pressure in heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Am Heart Assoc. 2020;9:e016009. https:\/\/doi.org\/10.1161\/JAHA.119.016009.","journal-title":"J Am Heart Assoc"},{"key":"3744_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","volume":"6","author":"SJ Shah","year":"2013","unstructured":"Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184\u201392. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.972794.","journal-title":"Circ Heart Fail"},{"key":"3744_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1053\/j.ajkd.2012.07.029","volume":"61","author":"D Bolignano","year":"2013","unstructured":"Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61:612\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.029. [published correction appears in Am J Kidney Dis. 2015;65:524. https:\/\/doi.org\/10.1053\/j.ajkd.2014.12.004.","journal-title":"Am J Kidney Dis"},{"key":"3744_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1681\/ASN.2015070819","volume":"27","author":"MJ Sarnak","year":"2016","unstructured":"Sarnak MJ, Roberts KE. Pulmonary hypertension in CKD: some answers, yet more questions. J Am Soc Nephrol. 2016;27:661\u20133. https:\/\/doi.org\/10.1681\/ASN.2015070819.","journal-title":"J Am Soc Nephrol"},{"key":"3744_CR32","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3892\/mmr.2017.6706","volume":"16","author":"Y Lu","year":"2017","unstructured":"Lu Y, Guo H, Sun Y, Pan X, Dong J, Gao D, et al. Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents. Mol Med Rep. 2017;16:1360\u20138. https:\/\/doi.org\/10.3892\/mmr.2017.6706.","journal-title":"Mol Med Rep"},{"key":"3744_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","volume":"293","author":"S Andersen","year":"2019","unstructured":"Andersen S, Axelsen JB, Ringgaard S, Nyengaard JR, Hyldebrandt JA, Bogaard HJ, et al. Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure. Int J Cardiol. 2019;293:203\u201310. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.065.","journal-title":"Int J Cardiol"},{"key":"3744_CR34","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.ijcha.2020.100486","volume":"27","author":"M Correale","year":"2020","unstructured":"Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, et al. Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart failure Registry. Int J Cardiol Heart Vasc. 2020;27:100486. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100486.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"3744_CR35","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.3390\/jcm9103159","volume":"9","author":"D Masarone","year":"2020","unstructured":"Masarone D, Errigo V, Melillo E, Valente F, Gravino R, Verrengia M, et al. Effects of Sacubitril\/Valsartan on the right ventricular arterial coupling in patients with heart failure with reduced ejection fraction. J Clin Med. 2020;9:3159. https:\/\/doi.org\/10.3390\/jcm9103159.","journal-title":"J Clin Med"}],"updated-by":[{"DOI":"10.1186\/s12872-024-03801-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000}}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-03744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-03744-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-03744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T04:03:48Z","timestamp":1709352228000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-03744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-03744-y","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12872-024-03801-6","URL":"https:\/\/doi.org\/10.1186\/s12872-024-03801-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Wuhan Central Hospital (Approval Document: 2016 Medical Research No. 03 and Hospital-Heng-Lun letter-2021 (9)). Informed consent was obtained from each patient, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}